Physician profile
Darren Wheeler
NPI 1487661161
$610,260.94
in general payments reported to CMS, 2019-2025
7 companies · $80K in 2025
The $80K reported for 2025 was more than what 99% of Anatomic Pathology providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $20K · 2021: $39K · 2022: $117K · 2023: $106K · 2024: $161K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $277K · Travel and Lodging: $64K · Food and Beverage: $6,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $276,802.87 |
| Travel and Lodging | $64,143.46 |
| Food and Beverage | $6,001.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gen-Probe, INC. | $434,226.48 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Hologic Sales and Service, LLC | $157,955.18 | 2019-2025 | Aptima, None, Fetal Fibronectin Enzyme Immunoassay |
| Gen-Probe Sales & Service, INC. | $14,202.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $3,483.59 | 2019-2023 | Enhertu |
| Hologic INC | $134.81 | 2021 | |
| Qol Medical, LLC | $130.74 | 2019 | |
| Roche Diagnostics Corporation | $127.18 | 2023 | Cintec Plus Cytology |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.